LAG3 is being targeted together with PD-1 in the dual immunomodulator MGD013 (ClinicalTrials.gov identifier: NCT03219268, phase I trial) whose objective is to inhibit both targets and induce a synergistic effect on tumor immunity, as previously shown in murine models [86]. Here, LAG3 is linked to neoplasm.